安宫黄体酮治疗慢性肺心病呼吸衰竭的临床研究

Clinical Observation on therapeutic effect of medroxyprogestsrone acetate on respiratory failure in patients with pulmonary heart disease

目的观察安宫黄体酮治疗慢性肺心病呼吸衰竭的临床应用价值。方法将６２例慢性肺心病合并呼吸衰竭的患者随机分为安宫黄体酮治疗组和未用安宫黄体酮的对照组，比较两组用药前后血气分析的变化。结果治疗组用药后ＰａＣＯ２较药前平均降低 １１．２ｍｍＨｇ（Ｐ＜．００１），ＰａＯ２较用药前平均升高 ７．９９ｍｍＨｇ（Ｐ<０．０５）。对照组用药后 ＰａＣＯ２较用药前平均降低 ８．９５ｍｍＨｇ （＞０．０５）， ＰａＯ２较用药前平均升高６．６３ｍｍＨｇ（Ｐ<０．０５）。治疗组与对照组相比，ＰａＣＯ２降低有非常显著性差异（Ｐ＜０．０１），ＰａＯ２升高有显著性差异（Ｐ<０．０５）。结论安宫黄体酮具有增强通气功能的药理作用。

Objective: To observe the effects of Medroxrprogesterone Acetate on respiratory failure in patients with pulmonary heart. disease.Methods: Sirly two patients were divided into two groups one treatment group of 32 cases another control group of 30 cases. Before and after treatment parameters about arterial blood gases were recorded, Results: After taking Medroxyprogesterone Acetate 12mg three times everyday for ten days, the value of arterial blood gases in the treatment group showed that PaCO2 was equally reduced 11.2mmHg (p<0.001), PaO2 was equally increased 7.99mmHg (P<0.05). However, PaCO2 in the control group Was equally reduced 8.95mmHg (P>0.05). But PaO2 was equally increased 6.63mmHg (P< 0.05). The result from determining arterial blood gases before and after treatment on the treatment group and the control group suggested that both PaCO2 reduction and PaO2 increment were statistically significant Conclusion: The Medroxyprogesterone Acetate is a safe, effective and simple respiratory stimulant.